Registration - In-house Corporation

Alexion Pharma Canada / Karen Heim, Vice President and General Manager, Alexion Pharma Canada

Registration Information

In-house Corporation name: Alexion Pharma Canada
Responsible Officer Name: Karen Heim, Vice President and General Manager, Alexion Pharma Canada
Responsible Officer Change History
Initial registration start date: 2017-06-09
Registration status: Active
Registration Number: 959365-360057

Associated Communications

Total Number of Communication Reports: 11

Monthly communication reports in the last 6 months: 0

Version 6 of 13 (2020-07-16 to 2021-01-29)

Registration versions:

Version 6 of 13 (2020-07-16 to 2021-01-29)

Lobbying Information

Subject Matters

Health
Industry
Intellectual Property

Subject Matter Details

Legislative Proposal, Bill or Resolution, Policies or Program, Regulation

Industry Patent Act, R.S.C., 1985, c. P-4. The Act as a whole falls under the jurisdiction of the Minister of Industry, with the exception of sections 79 to 103 pertaining to the Patented Medicines Pricing Review Board (PMPRB), which are the responsibility of the Minister of Health. The Minister of Health has launched a public consultation process which may amend the act, change regulations, and/or result in new policies or programs. Alexion Pharma Canada is participating in these consultations, and will raise awareness on how proposed changes will impact the life sciences industry in Canada and specifically development of innovative new treatments for rare diseases

Policies or Program

Research and Development General awareness on the importance of a strong research and development ecosystem in Canada to support ultra rare disease patients
Science and Technology The importance of including science and technology, and Canada's innovation potential, in federal policies

Regulation

Health - Patent Act, R.S.C., 1985, c. P-4. The Act as a whole falls under the jurisdiction of the Minister of Industry, with the exception of sections 79 to 103 pertaining to the Patented Medicines Pricing Review Board (PMPRB), which are the responsibility of the Minister of Health. The Minister of Health has launched a public consultation process which may amend the act, change regulations, and/or result in new policies or programs. Alexion Pharma Canada is participating in these consultations
Intellectual Property Amendments to the Food and Drugs Act: Guide to New Authorities (power to disclose information). Alexion wishes to raise awareness of the importance of considering intellectual property protection when deciding whether to make Confidential Business Information available to third-parties as Health Canada considers guidelines for the bill formerly referred to as C-17.

Communication Techniques

Written communication
Oral communication

Government Institutions

Global Affairs Canada (GAC)
Health Canada (HC)
House of Commons
Innovation, Science and Economic Development Canada (ISED)
Patented Medicine Prices Review Board (PMPRB)

In-house Corporation Details

Description of activities

Alexion pharma researches and develops treatments for ultra-rare, life threatening diseases

Responsible officer name and position during the period of this registration

Sean Richardson, Vice President and General Manager, Alexion Pharma Canada

Government funding

No government funding was received during the last completed financial year.

In-house Corporation Contact Information

Address:
3100 Rutherford Road
Vaughan, ON L4K 0G6
Canada

Telephone number: 416-356-3022

Parent Company Information

Alexion Pharma Inc.
- 100 College Street
  New Haven, CT 06510
  United States of America

Subsidiary Beneficiary Information

Alexion Pharma Canada does not have any subsidiaries that could have a direct interest in the outcome of the undertaking

Lobbyists Details

Senior Officers whose lobbying activities represent less than 20% of their Duties

Sean Richardson, Vice President and General Manager, Alexion Pharma Canada | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

Jason Locklin, Director, Global Government Affairs | No public offices held

Alexion Pharma Canada

The following names have been used on or after July 2, 2008

Name	From	To
Alexion Pharma Canada	2017-06-09	current

Alexion Pharma Canada

Responsible Officer History
Responsible Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)
Karen Heim	2024-10-01	Current
Christian Hansen	2021-11-01	2023-02-16
Sean Richardson	2020-07-16	2021-09-30
Daniel Palmqvist	2017-08-23	2020-07-16
John Haslam	2017-06-09	2017-08-23

Date Modified:: 2026-05-11

Search and menus

Language selection

Registration - In-house Corporation

Alexion Pharma Canada / Karen Heim, Vice President and General Manager, Alexion Pharma Canada

Registration Information

Associated Communications

Version 6 of 13 (2020-07-16 to 2021-01-29)

Version 6 of 13 (2020-07-16 to 2021-01-29)

Subject Matters

Subject Matter Details

Legislative Proposal, Bill or Resolution, Policies or Program, Regulation

Policies or Program

Regulation

Communication Techniques

Government Institutions

Description of activities

Responsible officer name and position during the period of this registration

Government funding

In-house Corporation Contact Information

Parent Company Information

Subsidiary Beneficiary Information

Senior Officers whose lobbying activities represent less than 20% of their Duties

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties